Latest Regulatory Progress News

Lefroy Exploration is nearing operational readiness at its Lucky Strike Gold Deposit with key approvals and designs in place, while gearing up for a high-grade drilling campaign at Burns Central. The company is fully funded and poised for a self-funded growth phase.

Boab Metals has extended its option to acquire full ownership of the Sorby Hills Project to the end of 2025, while locking in critical commercial agreements and environmental approvals that pave the way for a final investment decision.

Thor Energy has signed a term sheet with DISA Technologies to explore processing abandoned uranium waste dumps in Colorado, aiming to generate revenue without upfront costs using innovative HPSA technology.

Southern Palladium has initiated a comprehensive drilling campaign at its Bengwenyama PGM project, marking a critical step toward completing its Definitive Feasibility Study in early 2026. The program aims to refine metallurgical data and mine design while regulatory approvals edge closer.

Osteopore Limited has established OsteoRx, a new special purpose vehicle, with an initial AUD 0.5 million investment to accelerate breakthroughs in cellular regenerative medicine. This strategic move integrates a controlling stake in US-based RxCell Inc, expanding Osteopore’s footprint in the fast-growing stem cell market.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.

Neurotech International reported a 23% revenue drop and a doubling of its net loss to $10.6 million for FY25, driven by reduced R&D grants and high development costs. Despite financial pressures, the company marked significant clinical and regulatory progress for its NTI164 cannabinoid therapy.

Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.

Tissue Repair Ltd reported a 27.3% revenue increase to $3.22 million for FY25, driven by new distribution deals and regulatory progress, while continuing to invest heavily in clinical trials and manufacturing scale-up, resulting in a $4.24 million loss.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.